Abstract:Cigarette smoke, a toxic collection of more than 4000 chemicals generated from combustion of tobacco plant leaves, is known to cause several respiratory ailments, including chronic bronchitis, emphysema and lung cancer, and is associated with an increase in respiratory infections. In addition, cigarette smoking is considered a principal aetiological factor responsible for the development of certain diffuse interstitial and bronchiolar lung diseases, namely respiratory bronchiolitis-interstitial lung disease (RB-ILD), desquamative interstitial pneumonia (DIP) and adult pulmonary Langerhans’ cell histiocytosis (PLCH). Although not exclusively seen in cigarette smokers, substantial clinical and epidemiological data support a central role for smoking as the primary causative agent of most RB-ILD, DIP and PLCH. Additional evidence in support of cigarette smoke as a primary aetiological agent in RB-ILD, DIP and PLCH is the observation that smoking cessation may lead to disease improvement, while recurrence of these disorders has been observed to occur in the transplanted lung upon re-exposure to tobacco smoke. Furthermore, histopathological changes of respiratory bronchiolitis, DIP and PLCH (with or without co-existent emphysema) may be found on lung biopsy in the same individual, implicating smoking as a common inciting agent of these diverse lesions. Recent studies also suggest a role for cigarette smoking as a potential co-factor in the development of acute eosinophilic pneumonia, usual interstitial pneumonia and rheumatoid arthritis-associated interstitial lung disease. In the current review, we propose a novel classification that takes into account the complex relationship between cigarette smoking and diffuse lung diseases. Investigation on the role of smoking as a potential causative factor or modifier of these diverse diffuse lung diseases is important, as smoking cessation utilizing state-of-the-art tobacco cessation efforts should be a central part of therapy, while pharmacotherapy with corticosteroids or other immune modifying agents should be reserved for selected patients.

Smoking-related Small Airway Disease—A Review and Update

Small airways diseases, excluding asthma and COPD: an overview

Cigarette Smoking and Diffuse Lung Disease

Pathophysiology of the Small Airways in Chronic Obstructive Pulmonary Disease

Smoking-related interstitial lung disease: A narrative review

The pathology of small airways disease in COPD: historical aspects and future directions

The Contribution of Small Airway Obstruction to the Pathogenesis of Chronic Obstructive Pulmonary Disease

Small airways: an important but neglected target in the treatment of obstructive airway diseases

Small airway remodeling in diabetic and smoking chronic obstructive pulmonary disease patients

Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities

Smoking-related interstitial lung disease

Current Smoking Affects Gene Expression and Methylation Patterns in Asthma Patient Nasal Epithelium

Cigarette Smoke Induced Lung Barrier Dysfunction, EMT, and Tissue Remodeling: A Possible Link between COPD and Lung Cancer

Airway Remodeling in the Smoke Exposed Guinea Pig Model

Small airway determinants of airflow limitation in chronic obstructive pulmonary disease

Transforming growth factor-β1 and SMAD signalling pathway in the small airways of smokers and patients with COPD: potential role in driving fibrotic type-2 epithelial mesenchymal transition

Surfactant Proteins in Smoking-Related Lung Disease

Impact on Airway Remodeling

Epithelial and endothelial cell plasticity in chronic obstructive pulmonary disease (COPD)

Small airways disease in chronic obstructive pulmonary disease